Back to Search Start Over

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

Authors :
Dennis Teng
Hyung Kil Kim
Hyo Jong Kim
Young-Ho Kim
Sang-Bum Kang
Jun Lee
Do Hyun Kim
Seung Yong Shin
Kang-Moon Lee
Jong-Hwa Kim
Eun Soo Kim
Dong Il Park
Tae Oh Kim
Soo Jung Park
Jong Pil Im
Eun Sun Kim
Sung-Ae Jung
Chang Hwan Choi
Young Goo Kim
You Sun Kim
Sung Jae Shin
Wonyong Kim
Hyun-Chul Kim
Ji Won Kim
Source :
Intestinal Research. 20:350-360
Publication Year :
2022
Publisher :
Korean Association for the Study of Intestinal Diseases, 2022.

Abstract

Background/Aims: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).Methods: A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.Results: A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P

Details

ISSN :
22881956 and 15989100
Volume :
20
Database :
OpenAIRE
Journal :
Intestinal Research
Accession number :
edsair.doi.dedup.....a66e64660cf29c16b9cc58b0a28ddc36